Evidence map›Paper›PMID 23240586›Full record

ArticleAlcoholism, clinical and experimental research2013

Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey.

Sherry A McKee, Kelly C Young-Wolff, Emily L R Harrison, K Michael Cummings, Ron Borland, Christopher W Kahler, Geoffrey T Fong, Andrew Hyland

Open access · greenAbstract read
In one paragraph

Article in Alcoholism, clinical and experimental research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Progress in neuro-psychopharmacology & biological psychiatry · 2016
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Sherry A McKeeDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA. sherry.mckee@yale.edu
Kelly C Young-Wolff
Emily L R Harrison
K Michael Cummings
Ron Borland
Christopher W Kahler
Geoffrey T Fong
Andrew Hyland
Yale University · USRoswell Park Comprehensive Cancer Center · USBrown University · USCancer Council Victoria · AUOntario Institute for Cancer Research · CA

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
Project 3: Policy Effects on Cigarette Design, Emissions &BehaviorP50CA111236 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CUMMINGS, KENNETH MICHAEL · 2004 to 2009
$8.2M
Yale SCOR on Gender-Sensitive Treatment for Tobacco DependenceP50DA033945 · NIDA · YALE UNIVERSITY · PI MCKEE, SHERRY ANN · 2012 to 2017
$6.5M
International Tobacco Policy SurveyR01CA100362 · NCI · UNIVERSITY OF WATERLOO · PI FONG, GEOFFREY T · 2005 to 2013
$4.7M
Translational Neuroscience Research in Alcoholism (TNRA-TP)T32AA015496 · NIAAA · YALE UNIVERSITY · PI PETRAKIS, ISMENE L. · 2005 to 2014
$1.6M
Smoking cessation treatments and alcohol drinkingR01AA015596 · NIAAA · YALE UNIVERSITY · PI MCKEE, SHERRY ANN · 2006 to 2009
$1.2M
Dose ranging study of varenicline on human alcohol self-administration behaviorR01AA017976 · NIAAA · YALE UNIVERSITY · PI MCKEE, SHERRY ANN · 2009 to 2011
$1.0M
Cancer Research UK C312/A6465CIHR 79551NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA111236NCI NIH HHS R01 CA100362NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1RR024139NIAAA NIH HHS R01 AA015596NIAAA NIH HHS R01AA015596NIAAA NIH HHS R01 AA017976NIAAA NIH HHS R01AA017976NIAAA NIH HHS T32 AA015496NIAAA NIH HHS T32AA015496NIDA NIH HHS P50 DA033945
6 · The paper itself

Abstract

backgroundAvailable evidence suggests that quitting smoking does not alter alcohol consumption. However, smoking cessation medications may have a direct impact on alcohol consumption independent of any effects on smoking cessation. Using an international longitudinal epidemiological sample of smokers, we evaluated whether smoking cessation medications altered alcohol consumption independent of quitting smoking.

methodsLongitudinal data were analyzed from the International Tobacco Control Four Country (ITC-4) Survey between 2007 and 2008, a telephone survey of nationally representative samples of smokers from the United Kingdom, Australia, Canada, and the United States (n = 4,995). Quantity and frequency of alcohol consumption, use of smoking cessation medications (varenicline, nicotine replacement [NRT], and no medications), and smoking behavior were assessed across 2 yearly waves. Controlling for baseline drinking and changes in smoking status, we evaluated whether smoking cessation medications were associated with reduced alcohol consumption.

resultsVarenicline was associated with a reduced likelihood of any drinking compared with nicotine replacement (OR = 0.56; 95% CI = 0.34 to 0.94), and consuming alcohol once a month or more compared to nicotine replacement (OR = 0.43; 95% CI = 0.27 to 0.69) or no medication (OR = 0.63; 95% CI = 0.41 to 0.99). Nicotine replacement was associated with an increased likelihood of consuming alcohol once a month or more compared to no medication (OR = 1.14; 95% CI = 1.03 to 1.25). Smoking cessation medications were not associated with more frequent drinking (once a week or more) or typical quantity consumed per episode. Medication effects on drinking frequency were independent of smoking cessation.

conclusionsThis epidemiological investigation demonstrated that varenicline was associated with a reduced frequency of alcohol consumption. Continued work should clarify under what conditions nicotine replacement therapies may increase or decrease patterns of alcohol consumption.

Indexed as

AdultAlcohol DrinkingBenzazepinesFemaleHumansLongitudinal StudiesMaleMiddle AgedNicotinic AgonistsQuinoxalinesSmoking CessationTobacco Use Cessation DevicesVareniclineBenzazepinesNicotinic AgonistsQuinoxalinesVarenicline

Identifiers

PMID23240586
PMCPMC3610791
OpenAlexW2006793851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.